- November 21, 2023– Fundamental New Patent Covers Treatment of Multiple Sclerosis Into 2038 and Beyond – – Third U.S. Patent Directed to…
- November 14, 2023– Positive Interim Analysis from Phase 2 CALLIPER Trial Showed Improvements in Serum Neurofilament Light Chain for Vidofludimus Calcium, Consistent…
- November 7, 2023– Webcast to be Held at 8:00 am ET on November 14, 2023 – NEW YORK, November 7, 2023 – Immunic,…
- November 2, 2023NEW YORK, November 2, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…
- October 26, 2023NEW YORK, October 26, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…
- October 16, 2023NEW YORK, October 16, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…
- October 15, 2023NEW YORK, October 15, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…
- October 11, 2023– Improvement in Serum Neurofilament Light Chain (NfL) Observed in Both Treatment Arms ofVidofludimus Calcium Over Placebo – – NfL…
- October 9, 2023– 24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive Multiple Sclerosis…
- October 4, 2023NEW YORK, October 4, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…
